Journal article
Serum concentrations of brain-derived neurotrophic factor (BDNF) are decreased in colorectal cancer patients
GV Brierley, IK Priebe, L Purins, KYC Fung, B Tabor, T Lockett, E Nice, P Gibbs, J Tie, P McMurrick, J Moore, A Ruszkiewicz, A Burgess, LJ Cosgrove
CANCER BIOMARKERS | IOS PRESS | Published : 2013
DOI: 10.3233/CBM-130345
Abstract
OBJECTIVE: To determine the usefulness of brain-derived neurotrophic factor (BDNF) as a diagnostic biomarker for colorectal cancer (CRC). MATERIALS AND METHODS: ELISA immunoassay was used to examine BDNF concentrations in the sera of two different retrospective cohorts consisting of CRC patients and age/gender matched controls. Cohort 1 consisted of 99 controls and 97 CRC patients, whereas cohort 2 consisted of 47 controls and 91 CRC patients. RESULTS: In cohort 1, the median concentration of BDNF was significantly (p< 0.0001) lower in CRC patient samples (18.8 ng/mL, range 4.0-56.5 ng/mL) than control samples (23.4 ng/mL, range 3.0-43.1 ng/mL). This finding was validated in an independent p..
View full abstractGrants
Funding Acknowledgements
We thank the Victorian Cancer Biobank (Melbourne, Victoria) for their assistance with sample collection. This work was funded by the CSIRO Preventative Health National Research Flagship.